Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Narrative (Details)

v3.23.2
Licenses Acquired - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Apr. 27, 2023
Feb. 28, 2023
Oct. 11, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Stock offering, price per share   $ 5.25          
Expenses recognized       $ 32,142 $ 33,131 $ 71,648 $ 69,853
Avenue              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Common shares issued (in shares)     3,636,365        
Avenue | AnnJi Pharmaceutical Co              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Upfront fees payment   $ 3,000          
Amount reimbursable $ 1,000            
Payments of milestones $ 2,000            
Common shares issued (in shares)   831,618          
Stock offering, price per share   $ 2.10          
Expenses recognized   $ 900          
Avenue | AnnJi Pharmaceutical Co | Additional Indication Milestones              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Additional fees due   $ 27,500          
Common shares issued (in shares)   276,652          
Expenses recognized   $ 300          
Avenue | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Additional fees due   165,000          
Avenue | Minimum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Additional fees due   75,000          
Avenue | Maximum | AnnJi Pharmaceutical Co | First Indication Milestones              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payments of milestones   10,800          
Avenue | Maximum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Additional fees due   750,000          
Avenue | Maximum | DFD Agreement | AnnJi Pharmaceutical Co | First Indication Milestones              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Additional fees due   $ 14,500